{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:47:30Z","timestamp":1790380050332,"version":"4.1.0"},"reference-count":43,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T00:00:00Z","timestamp":1490313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>In any drug discovery and development effort, a reduction in the time of the lead optimization cycle is critical to decrease the time to license and reduce costs. In addition, ethical guidelines call for the more ethical use of animals to minimize the number of animals used and decrease their suffering. Therefore, any effort to develop drugs to treat cutaneous leishmaniasis requires multiple tiers of<jats:italic>in vivo<\/jats:italic>testing that start with higher-throughput efficacy assessments and progress to lower-throughput models with the most clinical relevance. Here, we describe the validation of a high-throughput, first-tier, noninvasive model of lesion suppression that uses an<jats:italic>in vivo<\/jats:italic>optical imaging technology for the initial screening of compounds. A strong correlation between luciferase activity and the parasite load at up to 18 days postinfection was found. This correlation allows the direct assessment of the effects of drug treatment on parasite burden. We demonstrate that there is a strong correlation between drug efficacy measured on day 18 postinfection and the suppression of lesion size by day 60 postinfection, which allows us to reach an accurate conclusion on drug efficacy in only 18 days. Compounds demonstrating a significant reduction in the bioluminescence signal compared to that in control animals can be tested in lower-throughput, more definitive tests of lesion cure in BALB\/c mice and Golden Syrian hamsters (GSH) using Old World and New World parasites.<\/jats:p>","DOI":"10.1128\/aac.02048-16","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T02:50:39Z","timestamp":1485831039000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":19,"title":["Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a Tiered<i>In Vivo<\/i>Screening Paradigm for Development of Drugs To Treat Cutaneous Leishmaniasis"],"prefix":"10.1128","volume":"61","author":[{"given":"Diana","family":"Caridha","sequence":"first","affiliation":[{"name":"Walter Reed Army Institute of Research, Experimental Therapeutics Branch of the Military Malaria Research Program, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandi","family":"Parriot","sequence":"additional","affiliation":[{"name":"Walter Reed Army Institute of Research, Experimental Therapeutics Branch of the Military Malaria Research Program, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Hudson","sequence":"additional","affiliation":[{"name":"Walter Reed Army Institute of Research, Experimental Therapeutics Branch of the Military Malaria Research Program, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lang","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Unit\u00e9 d'Immunophysiologie et Parasitisme Intracellulaire, D\u00e9partement de Parasitologie et Mycologie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklyn","family":"Ngundam","sequence":"additional","affiliation":[{"name":"Walter Reed Army Institute of Research, Experimental Therapeutics Branch of the Military Malaria Research Program, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Leed","sequence":"additional","affiliation":[{"name":"Walter Reed Army Institute of Research, Experimental Therapeutics Branch of the Military Malaria Research Program, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenell","family":"Sena","sequence":"additional","affiliation":[{"name":"Walter Reed Army Institute of Research, Experimental Therapeutics Branch of the Military Malaria Research Program, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Harris","sequence":"additional","affiliation":[{"name":"Walter Reed Army Institute of Research, Experimental Therapeutics Branch of the Military Malaria Research Program, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"O'Neil","sequence":"additional","affiliation":[{"name":"Walter Reed Army Institute of Research, Experimental Therapeutics Branch of the Military Malaria Research Program, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Sciotti","sequence":"additional","affiliation":[{"name":"Walter Reed Army Institute of Research, Experimental Therapeutics Branch of the Military Malaria Research Program, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Read","sequence":"additional","affiliation":[{"name":"Walter Reed Army Institute of Research, Experimental Therapeutics Branch of the Military Malaria Research Program, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Lecoeur","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Unit\u00e9 d'Immunophysiologie et Parasitisme Intracellulaire, D\u00e9partement de Parasitologie et Mycologie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hickman","sequence":"additional","affiliation":[{"name":"Walter Reed Army Institute of Research, Experimental Therapeutics Branch of the Military Malaria Research Program, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Grogl","sequence":"additional","affiliation":[{"name":"Walter Reed Army Institute of Research, Experimental Therapeutics Branch of the Military Malaria Research Program, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.19.1.111-126.2006"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2003.09.008"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cimid.2004.03.004"},{"key":"e_1_3_3_5_2","first-page":"399","article-title":"Current scenario of drug development for leishmaniasis","volume":"123","author":"Croft SL","year":"2006","unstructured":"Croft SL SeifertK YardleyV. 2006. Current scenario of drug development for leishmaniasis. Indian J Med Res123:399\u2013410.","journal-title":"Indian J Med Res"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003889"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3791\/3533"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0169-4758(95)80200-2"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0031182012002156"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0031182007003848"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.02083-14"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/00034983.1995.11813015"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2009.06.006"},{"key":"e_1_3_3_14_2","first-page":"27","article-title":"Visceral leishmaniasis: experimental models for drug discovery","volume":"133","author":"Gupta S","year":"2011","unstructured":"Gupta S , Nishi. 2011. Visceral leishmaniasis: experimental models for drug discovery. Indian J Med Res133:27\u201339.","journal-title":"Indian J Med Res"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01310-09"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.11.018"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2011.11.015"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00270-08"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000034"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001927"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-6851(00)00270-X"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exppara.2010.05.014"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003666"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1918"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exppara.2010.12.006"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exppara.2015.01.008"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.15-0448"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.3791\/1980"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.11-0812"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2002.66.273"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.12.6830-6834.2003"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.4103\/0974-777X.62887"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.6.1872-1875.2001"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803859"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.7.1504"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2005.01.009"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2004.05.024"},{"key":"e_1_3_3_38_2","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.4049\/jimmunol.154.10.5320","article-title":"IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis","volume":"154","author":"Scharton-Kersten T","year":"1995","unstructured":"Scharton-Kersten T AfonsoLC WysockaM TrinchieriG ScottP. 1995. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol154:5320\u20135330.","journal-title":"J Immunol"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0369-8114(03)00101-9"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011882"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir496"},{"key":"e_1_3_3_42_2","volume-title":"Guide for the care and use of laboratory animals","author":"National Research Council","year":"2011","unstructured":"National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.","edition":"8"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(90)90187-Z"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.9.2167"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02048-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02048-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:26:05Z","timestamp":1692663965000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02048-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1128\/AAC.02048-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.02048-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"2016-10-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-01-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02048-16"}}